Overall, the study of the role of PEITC in p53R248Q ESCC has led to a deeper understanding of the function of dietary compounds and p53 mutants, combined with the role of PEITC in breast cancer (SK-BR-3 (p53R175H), AU565 (p53R175H)) and prostate cancer (LAPC-4 (p53R175H) and VCaP (p53R248W)) (Aggarwal et al., 2016; Aggarwal et al., 2019), it is plausible that PEITC could be used in “basket trials” for cancers with selective p53 mutations, making it possible to develop new strategies for treating most cancers in the future. Here, TP53 is linked to prostate carcinoma.